Cargando…

Comparison of remission criteria in patients with rheumatoid arthritis treated with biologic or targeted synthetic disease-modifying anti-rheumatic drugs: results from a nationwide registry

BACKGROUND: Biologic or targeted synthetic disease-modifying anti-rheumatic drugs (b/tsDMARD) are widely used for treatment of rheumatoid arthritis (RA), enabling patients to better achieve remission. OBJECTIVE: The objective of the study was to investigate and compare remission rates in RA patients...

Descripción completa

Detalles Bibliográficos
Autores principales:	Koh, Jung Hee, Lee, Yusun, Kim, Hyoun-Ah, Kim, Jinhyun, Shin, Kichul
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2022
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9109493/ https://www.ncbi.nlm.nih.gov/pubmed/35586514 http://dx.doi.org/10.1177/1759720X221096363

Ejemplares similares

Implications of Persistent Pain in Patients With Rheumatoid Arthritis Despite Remission Status: Data From the KOBIO Registry
por: Kim, Hyoun-Ah, et al.
Publicado: (2022)

Unveiling difficult-to-treat rheumatoid arthritis: long-term impact of biologic or targeted synthetic DMARDs from the KOBIO registry
por: Jung, Ju-Yang, et al.
Publicado: (2023)

Differences in trajectory of disease activity according to biologic and targeted synthetic disease-modifying anti-rheumatic drug treatment in patients with rheumatoid arthritis
por: Koo, Bon San, et al.
Publicado: (2022)

Efficacy of Abatacept Versus Tumor Necrosis Factor Inhibitors in Anti-citrullinated Protein Antibody-Positive Patients with Rheumatoid Arthritis: Results from a Korean Nationwide Biologics Registry
por: Kim, Min Jung, et al.
Publicado: (2022)

The Aftermath of Tapering Tocilizumab After Achieving Treatment Target in Patients With Rheumatoid Arthritis: A Nationwide Cohort Study
por: Park, Jun Won, et al.
Publicado: (2022)

Validity of Remission Criteria in Rheumatoid Arthritis Compared to Ultrasound-Defined Remission
por: Ben Abdelghani, Kawther, et al.
Publicado: (2022)

Retention Rate and Safety of Biosimilar CT-P13 in Rheumatoid Arthritis: Data from the Korean College of Rheumatology Biologics Registry
por: Kim, Hyoun-Ah, et al.
Publicado: (2019)

Association between biologic disease modifying anti-rheumatic drugs and incident hypertension in patients with rheumatoid arthritis: Results from prospective nationwide KOBIO Registry
por: Kim, Seong-Kyu, et al.
Publicado: (2020)

Association between obesity and remission in rheumatoid arthritis patients treated with disease-modifying anti-rheumatic drugs
por: Abuhelwa, Ahmad Y., et al.
Publicado: (2020)

Factors Determining Retreatment Time Interval of Rituximab in Korean Patients With Rheumatoid Arthritis
por: Kim, Ji-Won, et al.
Publicado: (2021)

Performance of the 2015 American College of Rheumatology/European League against Rheumatism Classification Criteria for Gout in Korean Patients with Acute Arthritis
por: Choi, In Ah, et al.
Publicado: (2019)

Effect of biologics and targeted synthetic disease-modifying anti-rheumatic drugs on fatigue in rheumatoid arthritis
por: Choy, Ernest H
Publicado: (2019)

Long-term sustained remission in a cohort study of patients with rheumatoid arthritis: choice of remission criteria
por: Svensson, Björn, et al.
Publicado: (2013)

Brief Report: Remission Rates With Tofacitinib Treatment in Rheumatoid Arthritis: A Comparison of Various Remission Criteria
por: Smolen, Josef S., et al.
Publicado: (2017)

American College of Rheumatology/EULAR remission criteria for rheumatoid arthritis: 2022 revision
por: Studenic, Paul, et al.
Publicado: (2023)

American College of Rheumatology/EULAR Remission Criteria for Rheumatoid Arthritis: 2022 Revision
por: Studenic, Paul, et al.
Publicado: (2022)

Remission in Rheumatoid Arthritis
por: Shammas, Rania M., et al.
Publicado: (2010)

Prediction of remission and low disease activity in disease-modifying anti-rheumatic drug-refractory patients with rheumatoid arthritis treated with golimumab
por: Vastesaeger, Nathan, et al.
Publicado: (2016)

Factors Contributing to Discordance between the 2011 ACR/EULAR Criteria and Physician Clinical Judgment for the Identification of Remission in Patients with Rheumatoid Arthritis
por: Sung, Yoon-Kyoung, et al.
Publicado: (2016)

Comparative Cost-Effectiveness of Tofacitinib With Continuing Conventional Synthetic Disease-Modifying Anti-Rheumatic Drugs for Active Rheumatoid Arthritis in South Korea
por: Ha, So-Young, et al.
Publicado: (2021)

Rheumatoid arthritis serotype and synthetic disease-modifying anti-rheumatic drugs in patients with periodontitis: A case-control study
por: Nik-Azis, Nik-Madihah, et al.
Publicado: (2021)

Association of TLR 9 gene polymorphisms with remission in patients with rheumatoid arthritis receiving TNF-α inhibitors and development of machine learning models
por: Kim, Woorim, et al.
Publicado: (2021)

Gout, Rheumatism, and Rheumatoid Arthritis
Publicado: (1900)

Chronic Rheumatism and Rheumatoid Arthritis
por: Lindsay, J.
Publicado: (1908)

Use of biologic or targeted-synthetic disease-modifying anti-rheumatic drugs and risk of diabetes treatment intensification in patients with rheumatoid arthritis and diabetes mellitus
por: Chen, Sarah K, et al.
Publicado: (2020)

Treating to the target of remission in early rheumatoid arthritis is cost-effective: results of the DREAM registry
por: Vermeer, Marloes, et al.
Publicado: (2013)

Ultrasound remission in patients with rheumatoid arthritis in clinical remission
por: Fakhfakh, Rym, et al.
Publicado: (2021)

Prediction of sustained biologic and targeted synthetic DMARD-free remission in rheumatoid arthritis patients
por: Burkard, Theresa, et al.
Publicado: (2021)

Machine learning model for identifying important clinical features for predicting remission in patients with rheumatoid arthritis treated with biologics
por: Koo, Bon San, et al.
Publicado: (2021)

Application of the international league against rheumatism classification criteria for systemic juvenile idiopathic arthritis as a prognostic factor in patients with adults-onset Still’s disease
por: Yang, Ji Won, et al.
Publicado: (2018)

Prevalence and Fracture Risk of Osteoporosis in Patients with Rheumatoid Arthritis: A Multicenter Comparative Study of the FRAX and WHO Criteria
por: Choi, Sang Tae, et al.
Publicado: (2018)

Abatacept monotherapy compared with abatacept plus disease-modifying anti-rheumatic drugs in rheumatoid arthritis patients: data from the ORA registry
por: Truchetet, Marie-Elise, et al.
Publicado: (2016)

A Treatise on Rheumatism and Rheumatoid Arthritis
Publicado: (1892)

Persistence of Mast Cell-Positive Synovitis in Early Rheumatoid Arthritis Following Treatment With Conventional Synthetic Disease Modifying Anti-Rheumatic Drugs
por: Rivellese, Felice, et al.
Publicado: (2020)

Achieving comprehensive remission or low disease activity in rheumatoid patients and its impact on workability – Saudi Rheumatoid Arthritis Registry
por: Almoallim, Hani, et al.
Publicado: (2019)

Health-related Quality of Life Outcomes of Adalimumab for Patients With Rheumatoid Arthritis in Korea
por: Lee, Myeung-su, et al.
Publicado: (2021)

Elicitation of Rheumatologist Preferences for the Treatment of Patients with Rheumatoid Arthritis After the Failure of a First Conventional Synthetic Disease-Modifying Anti-Rheumatic Agent
por: Senbel, Eric, et al.
Publicado: (2021)

Validity and risk of adopting PGA ≤ 2 as a remission criteria of Boolean in clinical practice in patient with rheumatoid arthritis
por: Yoshii, Ichiro, et al.
Publicado: (2022)

Effectiveness of sequential biologic and targeted disease modifying anti-rheumatic drugs for rheumatoid arthritis
por: Zhao, Sizheng Steven, et al.
Publicado: (2022)

Disease-modifying anti-rheumatic drugs improve the cardiovascular profile in patients with rheumatoid arthritis
por: Giachi, Andrea, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_7il7s0463oobsfip12rs8khjbl